Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice.

Robling AG, Kedlaya R, Ellis SN, Childress PJ, Bidwell JP, Bellido T, Turner CH

Endocrinology7 Jun 2011Cited by 48 (Europe PMC)

PMID21652726PMCIDPMC3138236DOI10.1210/en.2011-0049PepBankPUB-21652726

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In Sost-deficient mice, distal femur trabecular bone was highly responsive to intermittent PTH.
In plain wordsIn mice lacking Sost, distal femur trabecular bone responded strongly to intermittent PTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedDistal femur trabecular bone response
Study
mousen: not reported in source
Sost-deficient and wild-type mice
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 or 90 μg/kg daily · injection · 6 wkAs given in this study (mouse).
Source sentences
Summary
Distal femur trabecular bone was highly responsive to iPTH in Sost(-/-) mice.
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated this mechanism by treating Sost-deficient mice and their wild-type littermates with anabolic and catabolic regimens of PTH and measuring the skeletal responses.
Summary · context
Male Sost(+/+) and Sost(-/-) mice were injected daily with human PTH 1-34 (0, 30, or 90 μg/kg) for 6 wk.
Summary · context
Female Sost(+/+) and Sost(-/-) mice were continuously infused with vehicle or high-dose PTH (40 μg/kg · d) for 3 wk.
Report a problemFND-2165272604

Studies that did not test the peptide alone6

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

02AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In mice, Sost deletion impaired intermittent PTH-induced bone gain measured by absorptiometry.
In plain wordsIn mice, Sost deletion reduced bone gain induced by intermittent PTH compared with wild-type mice.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseIntermittent PTH-induced bone gain
Study
mousen: not reported in source
Sost-deficient and wild-type mice
Comparator
Wild-type mice
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Dual energy x-ray absorptiometry-derived measures of intermittent PTH (iPTH)-induced bone gain were impaired in Sost(-/-) mice.
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated this mechanism by treating Sost-deficient mice and their wild-type littermates with anabolic and catabolic regimens of PTH and measuring the skeletal responses.
Summary · context
Male Sost(+/+) and Sost(-/-) mice were injected daily with human PTH 1-34 (0, 30, or 90 μg/kg) for 6 wk.
Summary · context
Female Sost(+/+) and Sost(-/-) mice were continuously infused with vehicle or high-dose PTH (40 μg/kg · d) for 3 wk.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2165272601
03AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In Sost-deficient mice, intermittent PTH-induced cortical bone formation rates were normal or enhanced.
In plain wordsIn mice, Sost deletion preserved or increased cortical bone formation induced by intermittent PTH compared with wild-type mice.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedCortical bone formation rates
Study
mousen: not reported in source
Sost-deficient and wild-type mice
Comparator
Wild-type mice
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Further probing revealed normal or enhanced iPTH-induced cortical bone formation rates but concomitant increases in cortical porosity among Sost(-/-) mice.
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated this mechanism by treating Sost-deficient mice and their wild-type littermates with anabolic and catabolic regimens of PTH and measuring the skeletal responses.
Summary · context
Male Sost(+/+) and Sost(-/-) mice were injected daily with human PTH 1-34 (0, 30, or 90 μg/kg) for 6 wk.
Summary · context
Female Sost(+/+) and Sost(-/-) mice were continuously infused with vehicle or high-dose PTH (40 μg/kg · d) for 3 wk.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2165272602
04AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In Sost-deficient mice, intermittent PTH responses included concomitant increases in cortical porosity.
In plain wordsIn mice lacking Sost, cortical porosity increased during intermittent PTH treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical porosity
Study
mousen: not reported in source
Sost-deficient and wild-type mice
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Further probing revealed normal or enhanced iPTH-induced cortical bone formation rates but concomitant increases in cortical porosity among Sost(-/-) mice.
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated this mechanism by treating Sost-deficient mice and their wild-type littermates with anabolic and catabolic regimens of PTH and measuring the skeletal responses.
Summary · context
Male Sost(+/+) and Sost(-/-) mice were injected daily with human PTH 1-34 (0, 30, or 90 μg/kg) for 6 wk.
Summary · context
Female Sost(+/+) and Sost(-/-) mice were continuously infused with vehicle or high-dose PTH (40 μg/kg · d) for 3 wk.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2165272603
05AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In mice receiving continuous PTH, Sost deletion did not alter bone loss measured by absorptiometry.
In plain wordsIn mice receiving continuous PTH, bone loss was equal in Sost-deficient and wild-type mice.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBone loss during continuous infusion
Study
mousen: not reported in source
Sost-deficient and wild-type mice
Comparator
Wild-type mice receiving continuous PTH
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Continuous PTH (cPTH) infusion resulted in equal bone loss in Sost(+/+) and Sost(-/-) mice as measured by dual energy x-ray absorptiometry.
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated this mechanism by treating Sost-deficient mice and their wild-type littermates with anabolic and catabolic regimens of PTH and measuring the skeletal responses.
Summary · context
Male Sost(+/+) and Sost(-/-) mice were injected daily with human PTH 1-34 (0, 30, or 90 μg/kg) for 6 wk.
Summary · context
Female Sost(+/+) and Sost(-/-) mice were continuously infused with vehicle or high-dose PTH (40 μg/kg · d) for 3 wk.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2165272605
06AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In mice, Sost deletion spared distal femur trabecular bone from continuous PTH-induced bone wasting.
In plain wordsIn mice, Sost deletion protected distal femur trabecular bone during continuous PTH treatment compared with wild-type mice.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseDistal femur trabecular bone loss
Study
mousen: not reported in source
Sost-deficient and wild-type mice
Comparator
Wild-type mice
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
However, distal femur trabecular bone, but not lumbar spine trabecular bone, was spared the bone-wasting effects of cPTH in Sost(-/-) mice.
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated this mechanism by treating Sost-deficient mice and their wild-type littermates with anabolic and catabolic regimens of PTH and measuring the skeletal responses.
Summary · context
Male Sost(+/+) and Sost(-/-) mice were injected daily with human PTH 1-34 (0, 30, or 90 μg/kg) for 6 wk.
Summary · context
Female Sost(+/+) and Sost(-/-) mice were continuously infused with vehicle or high-dose PTH (40 μg/kg · d) for 3 wk.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2165272606
07AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In mice, Sost deletion did not spare lumbar spine trabecular bone from continuous PTH-induced bone wasting.
In plain wordsIn mice, Sost deletion did not protect lumbar spine trabecular bone during continuous PTH treatment compared with wild-type mice.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLumbar spine trabecular bone loss
Study
mousen: not reported in source
Sost-deficient and wild-type mice
Comparator
Wild-type mice receiving continuous PTH
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
However, distal femur trabecular bone, but not lumbar spine trabecular bone, was spared the bone-wasting effects of cPTH in Sost(-/-) mice.
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated this mechanism by treating Sost-deficient mice and their wild-type littermates with anabolic and catabolic regimens of PTH and measuring the skeletal responses.
Summary · context
Male Sost(+/+) and Sost(-/-) mice were injected daily with human PTH 1-34 (0, 30, or 90 μg/kg) for 6 wk.
Summary · context
Female Sost(+/+) and Sost(-/-) mice were continuously infused with vehicle or high-dose PTH (40 μg/kg · d) for 3 wk.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2165272607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.